Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP)’s stock price has gone decline by -1.42 in comparison to its previous close of 0.20, however, the company has experienced a 53.55% increase in its stock price over the last five trading days. globenewswire.com reported 2024-11-21 that Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) — The “Muscarinic Acetylcholine Receptor M1 Antagonists – Pipeline Insight, 2024” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Is It Worth Investing in Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Right Now?
The stock has a 36-month beta value of 2.24. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TNXP is 186.89M, and at present, short sellers hold a 4.10% of that float. On November 22, 2024, the average trading volume of TNXP was 38.62M shares.
TNXP’s Market Performance
TNXP’s stock has seen a 53.55% increase for the week, with a 25.42% rise in the past month and a -46.18% fall in the past quarter. The volatility ratio for the week is 24.27%, and the volatility levels for the past 30 days are at 13.25% for Tonix Pharmaceuticals Holding Corp The simple moving average for the past 20 days is 30.68% for TNXP’s stock, with a -94.22% simple moving average for the past 200 days.
Analysts’ Opinion of TNXP
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $4. The rating they have provided for TNXP stocks is “Buy” according to the report published on April 18th, 2019.
ROTH Capital gave a rating of “Buy” to TNXP, setting the target price at $6 in the report published on August 18th of the previous year.
TNXP Trading at 33.00% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.09% of loss for the given period.
Volatility was left at 13.25%, however, over the last 30 days, the volatility rate increased by 24.27%, as shares surge +20.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.49% upper at present.
During the last 5 trading sessions, TNXP rose by +52.48%, which changed the moving average for the period of 200-days by -98.11% in comparison to the 20-day moving average, which settled at $0.1540. In addition, Tonix Pharmaceuticals Holding Corp saw -98.44% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TNXP
Current profitability levels for the company are sitting at:
- -7.31 for the present operating margin
- 0.08 for the gross margin
The net margin for Tonix Pharmaceuticals Holding Corp stands at -11.98. The total capital return value is set at -1.03. Equity return is now at value -138.69, with -115.46 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp (TNXP), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -13.14.
Currently, EBITDA for the company is -114.09 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 1.61. The receivables turnover for the company is 2.81for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.33.
Conclusion
To sum up, Tonix Pharmaceuticals Holding Corp (TNXP) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
